Treatment of anaerobic infections with metronidazole

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Metronidazole was used parenterally and orally to treat thirty patients with a variety of anaerobic and mixed infections. Other antimicrobial agents with activity against infecting anaerobes were not used or had failed. Sixteen patients (53%) were cured, thirteen (43%) were improved; and one (3%) failed to respond. Cultures during therapy disclosed no anaerobic pathogens in 24 of 26 (92%). Clinical failure (one patient) and the continuing presence of anaerobic pathogens (two patients) were associated with initially inadequate surgical procedures. Peak plasma levels achieved with doses of approximately 30 mg/kg/day in 26 patients were 21.0 ± 7.2 μg/ml. Slightly higher peak levels were achieved when this dose was preceded by a loading dose of 15 mg/kg. Side effects were infrequent and mild: pruritus with rash: 3 (10%); nausea: 5 (17%); and metallic taste: 2 (7%).

Original languageEnglish (US)
Pages (from-to)651-663
Number of pages13
JournalCurrent Therapeutic Research - Clinical and Experimental
Volume27
Issue number5
StatePublished - Jan 1 1980

Fingerprint

Metronidazole
Infection
Taste Disorders
Therapeutics
Pruritus
Anti-Infective Agents
Exanthema
Coinfection
Nausea

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Treatment of anaerobic infections with metronidazole. / Rissing, J. P.; Moore, W. L.; Newman, Cheryl L.

In: Current Therapeutic Research - Clinical and Experimental, Vol. 27, No. 5, 01.01.1980, p. 651-663.

Research output: Contribution to journalArticle

@article{d421adc7e95d4793a5f54774457316f1,
title = "Treatment of anaerobic infections with metronidazole",
abstract = "Metronidazole was used parenterally and orally to treat thirty patients with a variety of anaerobic and mixed infections. Other antimicrobial agents with activity against infecting anaerobes were not used or had failed. Sixteen patients (53{\%}) were cured, thirteen (43{\%}) were improved; and one (3{\%}) failed to respond. Cultures during therapy disclosed no anaerobic pathogens in 24 of 26 (92{\%}). Clinical failure (one patient) and the continuing presence of anaerobic pathogens (two patients) were associated with initially inadequate surgical procedures. Peak plasma levels achieved with doses of approximately 30 mg/kg/day in 26 patients were 21.0 ± 7.2 μg/ml. Slightly higher peak levels were achieved when this dose was preceded by a loading dose of 15 mg/kg. Side effects were infrequent and mild: pruritus with rash: 3 (10{\%}); nausea: 5 (17{\%}); and metallic taste: 2 (7{\%}).",
author = "Rissing, {J. P.} and Moore, {W. L.} and Newman, {Cheryl L}",
year = "1980",
month = "1",
day = "1",
language = "English (US)",
volume = "27",
pages = "651--663",
journal = "Current Therapeutic Research",
issn = "0011-393X",
publisher = "Excerpta Medica",
number = "5",

}

TY - JOUR

T1 - Treatment of anaerobic infections with metronidazole

AU - Rissing, J. P.

AU - Moore, W. L.

AU - Newman, Cheryl L

PY - 1980/1/1

Y1 - 1980/1/1

N2 - Metronidazole was used parenterally and orally to treat thirty patients with a variety of anaerobic and mixed infections. Other antimicrobial agents with activity against infecting anaerobes were not used or had failed. Sixteen patients (53%) were cured, thirteen (43%) were improved; and one (3%) failed to respond. Cultures during therapy disclosed no anaerobic pathogens in 24 of 26 (92%). Clinical failure (one patient) and the continuing presence of anaerobic pathogens (two patients) were associated with initially inadequate surgical procedures. Peak plasma levels achieved with doses of approximately 30 mg/kg/day in 26 patients were 21.0 ± 7.2 μg/ml. Slightly higher peak levels were achieved when this dose was preceded by a loading dose of 15 mg/kg. Side effects were infrequent and mild: pruritus with rash: 3 (10%); nausea: 5 (17%); and metallic taste: 2 (7%).

AB - Metronidazole was used parenterally and orally to treat thirty patients with a variety of anaerobic and mixed infections. Other antimicrobial agents with activity against infecting anaerobes were not used or had failed. Sixteen patients (53%) were cured, thirteen (43%) were improved; and one (3%) failed to respond. Cultures during therapy disclosed no anaerobic pathogens in 24 of 26 (92%). Clinical failure (one patient) and the continuing presence of anaerobic pathogens (two patients) were associated with initially inadequate surgical procedures. Peak plasma levels achieved with doses of approximately 30 mg/kg/day in 26 patients were 21.0 ± 7.2 μg/ml. Slightly higher peak levels were achieved when this dose was preceded by a loading dose of 15 mg/kg. Side effects were infrequent and mild: pruritus with rash: 3 (10%); nausea: 5 (17%); and metallic taste: 2 (7%).

UR - http://www.scopus.com/inward/record.url?scp=0018898759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018898759&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0018898759

VL - 27

SP - 651

EP - 663

JO - Current Therapeutic Research

JF - Current Therapeutic Research

SN - 0011-393X

IS - 5

ER -